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Abstract
Background: Cystatin C is a constitutively expressed and abundant cysteine protease inhibitor within the
cerebrospinal fluid (CSF). Recent studies have reported a significant reduction in cystatin C concentration in the CSF
of patients with amyotrophic lateral sclerosis (ALS) and several other neurodegenerative diseases, relative to healthy
controls. Cystatin C can exhibit both neuroprotective and neurotoxic properties, suggesting that altered CSF
cystatin C concentrations could potentially impact the pathogenesis or progression of these disorders. However, it
is unclear if alterations in cystatin C concentration result in physiologically relevant differences in its functional
activity within the CSF. Measurements of the cysteine protease inhibitory activity of cystatin C within the CSF have
not been reported, and the relationship between CSF cystatin C concentration and activity levels in different
disease contexts has not been investigated.
Methods: We used a papain inhibition assay to evaluate the total cystatin C activity in CSF samples from 23 ALS
patients, 23 healthy controls, and 23 neurological disease controls. Cystatin C concentrations in these samples were
previously measured by ELISA. Correlations between cystatin C concentration and activity were assessed with
nonparametric statistics. Activity ratios were compared among diagnostic groups using both one-way ANOVA and
repeated measures statistics.
Results: Total cystatin C activity was found to be directly proportional to its protein concentration in all subjects,
and cystatin C activity was not altered in ALS patients. In addition, our data suggest that cystatin C is the
predominant cysteine protease inhibitor in human CSF.
Conclusions: Our data demonstrate the successful measurement of the functional activity of cystatin C in the CSF,
and show that total cystatin C activity can be inferred from its total protein concentration. Our results also suggest
that cystatin C is the major cysteine protease inhibitor in human CSF and altered CSF cystatin C concentration may
play a role in the pathobiology of ALS and other neurological diseases.
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Background
Cystatin C is a low molecular weight cysteine protease
inhibitor that modulates protein degradation and cellmatrix interactions [1]. This protein binds with high
affinity to papain, cathepsins B, H and L, calpain, and
dipeptidyl peptidase, regulating both intracellular and
extracellular cysteine proteases [2]. Cystatin C is pro* Correspondence: Robert.bowser@dignityhealth.org
1
Department of Pathology, University of Pittsburgh School of Medicine,
Pittsburgh, PA, USA
2
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duced by nearly all cells and is secreted into the extracellular space, blood, or cerebrospinal fluid (CSF).
In the central nervous system (CNS), cystatin C is synthesized by choroid plexus cells and secreted into the
CSF. Interestingly, cystatin C is 5-fold more concentrated in the CSF than in the bloodstream [3]. This suggests that cystatin C may have important functions
within the CSF relating to the modulation of protein
degradation and, potentially, the regulation of multiple
signaling pathways [4].
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Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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We and others have reported that cystatin C levels are
reduced in the CSF of patients with amyotrophic lateral
sclerosis (ALS) when compared to both healthy controls
and neurological disease controls [5-9]. Altered levels
of CSF cystatin C have also been reported for other
neurological disorders including multiple sclerosis,
Alzheimer’s disease, and Creutzfeldt-Jakob disease
[10-12]. The reduction of CSF cystatin C levels in patients with multiple sclerosis and other inflammatory
diseases suggests that cystatin C has a role in modulating neuroinflammation. Indeed, some activity of this
type has been demonstrated in cell culture models
[13,14]. In addition, cystatin C has been shown to exhibit both neuroprotective and neurotoxic properties
within in vitro and in vivo models. Therefore, cystatin C
may have multiple functions relevant to the pathogenesis
and progression of neurological disease. However, the influence of altered cystatin C levels in this context remains unclear.
While the alteration of CSF cystatin C concentration
in various neurological disorders has been established,
the relationship between the concentration and functional activity of this protein within the CSF is unknown.
It is possible that CSF cystatin C exhibits simple, linear
activity kinetics at all physiologic concentrations, such
that it’s mean activity is a constant multiple of its total
concentration. Alternatively, cystatin C may demonstrate
concentration-dependent activity kinetics in vivo,
resulting in activity differences that are either magnified
or diminished relative to concentration differences.
Along different lines, it is also possible that the posttranslational modification or proteolytic processing of
cystatin C is altered in some disease states, potentially
resulting in altered baseline activity kinetics for the
protein.
Once the concentration-to-activity relationship is
clarified, it will be possible to draw conclusions about
the potential effects of altered cystatin C concentration
in neurological disease states. If the observed differences
in CSF cystatin C concentration do result in significant
changes in its cysteine protease inhibitory activity, this
could directly impact the protein milieu of the CSF, alter
the extracellular matrix within the CNS, and influence
downstream signaling events, potentially generating either neurotoxic or neuroprotective effects.
To determine the relationship between cystatin C concentration and functional activity within the CSF, we
modified a papain inhibition assay to enable the measurement of the protease inhibitory activity of cystatin C
in this biofluid. We used this assay to evaluate cystatin
C activity in CSF samples from a total of 69 ALS patients, healthy controls, and disease controls. We found
that the functional activity of cystatin C within the CSF
is directly related to its protein concentration, and that
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reduced cystatin C protein levels in the CSF of ALS patients likely correspond to reduced cysteine protease inhibitory activity. Our results provide an assay to
measure cystatin C activity in CSF and suggest a functional consequence of reduced CSF cystatin C levels in
ALS patients.

Methods
Samples

For this study, we selected 69 independent CSF samples
that were recently utilized in cystatin C biomarker discovery efforts [9]. Sample collection procedures were
approved by the institutional review board (IRB) at the
University of Pittsburgh, and written informed consent
was obtained from all participating subjects. Patient
demographics are shown in Table 1. The ALS group
included 18 patients with sporadic ALS and five with
familial ALS. ALS subjects were diagnosed by experienced neurologists specializing in motor neuron disease,
and all were classified as having probable, probablelaboratory-supported, or definite ALS according to El
Escorial criteria. Healthy control (HC) research subjects
lacked any neurological symptoms, and neurological disease controls (DC) included four patients with multiple
sclerosis, two each with primary lateral sclerosis, chronic
inflammatory demyelinating polyneuropathy, and progressive muscular atrophy, and one each with
spinocerebellar ataxia, small fiber neuropathy, idiopathic
sensorimotor polyneuropathy, bilateral facial palsies,
neurosarcoidosis, viral encephalitis, CNS lymphoma,
brain metastases, pseudotumor cerebri, seizure disorder,
complicated migraine, paresthesis with possible myelopathy, and probable conversion disorder.
The total cystatin C concentration in each of the 69
CSF samples was previously determined by ELISA [9].
Immunoprecipitation

For these experiments, the single CSF sample with the
highest concentration of cystatin C was used. Immunoprecipitation (IP) of cystatin C from CSF was performed
using a magnetic bead system (MACS Molecular,
Auburn, CA). First, varying amounts (0, 0.4, 0.8, or
1.6 μg) of affinity-purified goat anti-human cystatin C
polyclonal antibody (R&D Systems, Minneapolis, MN)
were added to 18 μL aliquots of CSF and the solutions
Table 1 Demographic characteristics of study participants
ALS
Healthy controls
(n = 23) (n = 23)

Disease controls
(n = 23)

Sex (male/female) 11/12

11/12

12/11

Age at draw ± SD
(years)

48.7 ± 14.2

48.5 ± 15.4

48.7 ±
13.9

There were no significant differences between subject age or gender
among groups.
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were briefly mixed at room temperature. Next, 100 μL
of Protein A MicroBeads were added to each aliquot,
and the solutions were mixed and incubated for 30 min
on ice. During this incubation, the μ columns (MACS
Molecular, Auburn, CA) were each primed with 200 μL
of lysis buffer (50 mM Tris HCl, pH = 6.00; 150 mM
NaCl; 1% Triton-X-100) and rinsed with 100 μL of assay
buffer (see Papain inhibition assay below). Next, the CSF
solutions were applied to the μ columns and the "flowthrough" was collected. An additional 30 μL of assay
buffer were then added to flush the remaining CSF solutions into the same flow-through collection tube. The
columns were each rinsed with 50 μL of PBS and the
combined flow-through solutions from all three steps
were saved. The columns were then rinsed with an additional 750 μL of PBS and 100 μL of low-salt wash buffer
(50 mM Tris HCl, pH 6.8; 50 mM DTT; 1% SDS;
0.005% bromophenol blue; 10% glycerol). To elute the
isolated cystatin C, 20 μL of pre-heated 1X SDS gel loading buffer were added to each μ column and incubated
for 5 min at room temperature. Next, an additional 50
μL of pre-heated 1X SDS gel loading buffer were added
and the elution products were collected. For subsequent
IPs of flow-through solutions, 4 μL (0.8 μg) of anticystatin C antibody and 100 μL of MicroBeads were
added to each flow-through sample, and the remaining
steps were repeated as above.
Immunoblotting

IP elution products were separated by electrophoresis on
a NuPAGEW NovexW 12% Bis-Tris polyacrylamide gel
(Invitrogen, Carlsbad, CA), with 20 μl per gel lane. The
proteins were transferred onto a PolyScreen polyvinylidene difluoride membrane (NEN Biolabs, Ipswich,
MA) and blocked with 5% nonfat milk in 1X TBS/0.05%
Tween-20 (TBST) for one hour at room temperature. A
mouse monoclonal anti-human cystatin C primary antibody (Santa Cruz Biotechnology, Santa Cruz, CA) was
added to the blocking solution at a 1:1000 dilution and
incubated overnight at 4°C. The membrane was thoroughly washed with TBST, and then a goat anti-mouse
horseradish peroxidase-conjugated secondary antibody
(Millipore, Burlington, MA) was diluted by 1:5000 in 5%
nonfat milk in TBST and applied to the membrane for
two hours at room temperature. The membrane was
thoroughly washed with TBST, and then the labelled
proteins were visualized using Chemiluminescence
Reagent Plus (PerkinElmer, Waltham, MA).

Papain inhibition assay
Assay procedure

The procedure we developed for this study was modified
from an R&D Systems activity assay protocol for
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recombinant human cystatin C protein (R&D Systems,
Minneapolis, MN). Plant-derived papain (Sigma, St.
Louis, MO) was diluted to 100 μg/mL in ice-cold activation buffer (50 mM Tris, 5 mM DTT, pH 7) and incubated at room temperature for 15 min. During this
incubation, CSF samples from each patient were diluted
at a 2:1 ratio by volume in either assay buffer (50 mM
Tris, pH 7) or polyclonal cystatin C blocking antibody
(R&D Systems, Minneapolis, MN; diluted to 0.2 mg/mL
in assay buffer) and incubated with gentle agitation for
five min at room temperature. The CSF sample solutions
were then further diluted 1:8 in assay buffer, and the activated papain solution was further diluted in assay buffer to 2 ug/mL. Equal volumes of the CSF and papain
solutions were mixed and incubated at 37°C for 10 min.
We next diluted the mixture 1:5 in assay buffer, and 50
μL were added to each well of a 96-well plate. 50 μL of
ZPheArgAMC (R&D Systems, Minneapolis, MN) substrate (10 mM in DMSO, diluted to 200 μM in assay
buffer) was rapidly added to each well, and the plate was
immediately inserted into a plate reader. The plate was
read for 5 min in kinetic mode, using excitation and emission wavelengths of 380 nm and 460 nm, respectively.

Assay design

Samples were randomized to plates and plate positions,
and assayed in triplicate. Each sample, and its corresponding sample/antibody solution, were always assayed
in adjacent wells. A standard curve and an internal
standard of mixed CSF were also included on each plate
for quality control. The experiment was repeated with
samples in reverse order on each plate to control for
slight assay differences based on plate position. All experiments were performed at least twice.
Statistical analysis

All statistics were carried out using SPSS software. Data
normality was assessed by the Kolmogorov-Smirnova
and Shapiro-Wilk tests, and normality was only assumed
when indicated by both tests. All calculated p-values
were two-tailed, and the significance level was set at
p < 0.05.
Papain inhibition assay data analysis

For each experiment, the reaction rate for each well was
determined as slope of best-fit line of graphed RFU data.
Intra-assay coefficients of variation (CVs) were calculated using the three reaction rates for each sample, and
each sample/antibody mixture, on each plate. Data from
one of the triplicate well readings was dropped from the
analyses when it differed from both other wells by a
CV ≥ 40, and the other two sample wells differed from
each other by a CV less than half of the average CV
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between the outlier and the similar wells. This eliminated only 0.65% of the assay data points (6 of 930 data
points). The average reaction rate for each raw CSF sample (without blocking antibody) was recorded as the total
assay activity for that sample. The total assay activity
was then subtracted from the average reaction rate for
the same sample containing blocking antibody to determine the total cystatin C activity for that sample.
All experiments were performed in triplicate and each
experiment repeated at least twice. Inter-assay CVs were
also determined for each sample using the total assay activity and, separately, the total cystatin C activity calculated for each separate experiment using the same
guidelines described above.
Coefficients of variation between duplicate/triplicate
wells for each sample run, and between mean cystatin C
activity plate results for each sample, were recalculated
after dropping outlier data as described above. Because
both groups of CV data failed normality, median values
were calculated as the measure of central tendency. The
overall intra-assay CV was calculated as the median of
the individual CVs for all sample-runs. The CVs were
non-normally distributed (range: 0.1–29.9%), and the
median (3.6%) was less than the generally acceptable
value for intra-assay variability (CV < 10%). Similarly,
inter-assay CVs were determined using the final cystatin
C activity level determined in each replicate experiment
for each CSF sample. The CVs were non-normally distributed (range: 0.2–32.1%), and the median (9.1%) was
well within the acceptable range for inter-assay variability (CV < 20%) [15].
Correlation analysis

The correlations between cystatin C concentration and
both assay activity and cystatin C activity in all samples as
a combined group were assessed using non-parametric
statistics because the data for total assay activity were
non-normally distributed. For these analyses, SPSS software was used to calculate both the Spearman correlation coefficient and the two-tailed significance level.
Identical methods were used to assess the same correlations in each diagnostic group because cystatin C
concentrations in ALS patients also failed normality
testing.
Comparison between diagnostic groups

Because cystatin C activity ratios were normally distributed in all three experimental groups and there were no
significant differences among group variances, we compared group means by one-way ANOVA.
For our final comparison of cystatin C concentration,
total assay activity, and total cystatin C activity between
groups, all diagnostic group data were normally distributed except for cystatin C concentration. For each data
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category, differences among diagnostic group means
were identified by one-way ANOVA.
Analysis of samples paired by cystatin C concentration

Samples in all three diagnostic groups were paired by
cystatin C concentration, and the seven samples in each
group which could not be paired with samples from the
other groups were dropped from this analysis. All paired
data for cystatin C concentration, total assay activity,
total cystatin C activity, and cystatin C activity ratio were
normally distributed. Therefore, we were able to use the
SPSS general linear model for repeated measures to assess differences in each of the four variables among diagnostic groups.

Results
Papain inhibition assay to measure cystatin C activity

To measure cystatin C protease inhibitory activity in the
cerebrospinal fluid (CSF), we utilized a papain inhibition
assay. Papain is a plant-derived cysteine protease that can
hydrolyze the Arg-AMC amide bond of a Z-Phe-ArgAMC substrate to release the fluorescent 7-amino-4-methyl coumarin (AMC) group. Relative fluorescence units
(RFU) are then measured over time to determine the total
papain activity. When a cysteine protease inhibitor (CPI)
is added to the assay solution, it inhibits papain-mediated
Z-F-R-AMC substrate cleavage, and fluorescence emission is reduced. The total activity of the CPI can then be
estimated as the reduction in papain-mediated assay
activity.
There are several challenges when using this assay to
measure the activity of a specific CPI within a biofluid
sample, such as CSF. First, because CSF contains several
CPIs, the total assay inhibition is a measure of the combined CPI activity and cannot be attributed to a single
protein. Additionally, CSF also contains endogenous
cysteine proteases that could potentially cleave the
Z-F-R-AMC substrate and supplement papain activity.
This would increase the overall fluorescence emission
and decrease the apparent CPI activity determined by
the assay.
To control for these factors, we determined the total cystatin C activity in CSF by assaying both raw CSF,
and CSF from the same patient sample that had been
pre-incubated with an antibody that blocks cystatin C
activity. For raw CSF samples, the total measured assay
activity included the supplementary effects of all endogenous cysteine proteases as well as the inhibitory effects of all CPIs present in the sample. For the CSF
treated with the blocking antibody, the measured assay
activity included all of the factors present in raw CSF except for the inhibitory activity of cystatin C. Therefore,
the total inhibitory activity of cystatin C in each sample
could be calculated by subtracting the total assay activity
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for raw CSF from the total assay activity for CSF treated
with the blocking antibody.

Table 2 Dose-dependent effect of cystatin C activityblocking antibody
Sample

CSF to antibody ratio
(by volume)

Mean assay activity
(RFU/min)

Specificity and efficiency of cystatin C blocking antibody

1

0:4

3737

Experiments were first conducted to test the effectiveness of the polyclonal anti-cystatin C antibody in both
binding to human cystatin C within CSF and in eliminating cystatin C activity from CSF samples. First, varying
amounts of the antibody were used to immunoprecipitate (IP) cystatin C from the CSF. Western blots were
then performed to assess the relative amounts of cystatin
C removed from each sample aliquot by IP, as well as
the amount remaining in each sample (Figure 1). We
found that the selected antibody effectively precipitated
cystatin C from human CSF, and that 1.6 μg of antibody
(in 8 μL volume) was adequate to fully remove cystatin
C from 18 μL of CSF (approximate 2:1 CSF to antibody
volumetric ratio).
Next, CSF aliquots from the same sample were preincubated with varying amounts of the same polyclonal
"blocking" antibody and used in the papain inhibition
assay as described in Methods. We observed an antibody
dose-dependent elimination of cystatin C inhibitory activity, with full elimination of function achieved by a
sample to antibody ratio of 2:1, by volume in a CSF sample that contained the highest amount of cystatin C protein as determined by ELISA (Table 2). This antibody
ratio was effective at fully eliminating activity in numerous CSF samples across a range of cystatin C protein
levels (data not shown). These findings confirm that this
polyclonal antibody can effectively bind to human
cystatin C and eliminate its functional activity from human CSF samples.

2

4:0

754

3

4:1

2455

4

4:2

3944

5

4:3

3799

6

4:4

3603

1 2 3 4 5 6 7 8 9
Cystatin
C

−15 kDa
−10 kDa

Figure 1 Depletion of cystatin C from CSF by
immunoprecipitation. Lanes 1–4: Increasing amounts of anticystatin C polyclonal antibody (0–1.6 μg antibody) was added to
CSF for immunoprecipitation as described in Methods. The resulting
immunoprecipitate was analysed by western blot for cystatin C.
Lane 1: 1.6 μg antibody (IP1); Lane 2: 0.8 μg antibody (IP2); Lane 3:
0.4 μg antibody; (IP3) Lane 4: 0 μg antibody (IP4). The remaining
column flow-through from each sample was then used to repeat
the cystatin C immunoprecipitation using 0.8 μg antibody to
examine efficiency of cystatin C removal during the initial
immunoprecipitation. Lane 5: Flow-through from IP1; Lane 6: Flowthrough from IP2; Lane 7: Flow-through from IP3; Lane 8: Flowthrough from IP4; Lane 9: Human cystatin C purified protein as a
positive control from a separate gel.

A CSF sample with the highest cystatin C concentration was pre-incubated with
varying amounts of polyclonal cystatin C activity-blocking antibody (samples
2–6) and then tested in the papain inhibition assay. Sample 1 demonstrates the
baseline papain assay activity in the absence of CSF-mediated papain inhibition
and in the presence of the highest dose of anti-cystatin C antibody used in the
experiment. Sample 2 demonstrates the maximal papain assay inhibition
produced by the CSF without any anti-cystatin C antibody. Addition of the
blocking antibody in samples 3–6 produces a dose-dependent elimination of
CSF-mediated assay inhibition, with full elimination reached at a 4:2 ratio
(where assay activity first returns to baseline). Cystatin C antibody was
prepared at a 0.2 μg/μL concentration.

Relationship between CSF cystatin C concentration and
activity

This 2:1 sample to antibody ratio was used to perform
the papain inhibition assay in all CSF samples to determine cystatin C functional activity in each sample. Before separating the data into diagnostic groups, we
graphed both total assay activity and total cystatin C activity versus the cystatin C concentration for each sample. We observed a strong, indirect relationship between
CSF cystatin C concentration and total papain assay activity (Figure 2A), and a strong, direct relationship between cystatin C concentration and its own activity
(Figure 2B). Next, the data were sorted into diagnostic
categories and these correlation analyses were repeated.
The relationships observed in the combined data were
maintained in all three individual diagnostic categories,
and all correlations were statistically significant, with
p < 0.001 and Spearman r values between -0.86 to -0.91
for each individual subject group cystatin C and total papain assay activity.

Comparison between diagnostic groups

We next compared CSF cystatin C concentration and activity levels among the three diagnostic groups (Table 3).
The mean cystatin C concentration was reduced in ALS
patients compared to the DC and HC groups as previously reported [9], but this difference did not reach
statistical significance. The low mean cystatin C concentration in ALS patients corresponded with the greatest
mean papain assay activity out of the three diagnostic
groups. The differences in mean cystatin C activity between diagnostic groups directly mirrored the group
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Figure 2 Correlation of cystatin C concentration with papain inhibition assay activity and cystatin C activity. (A) Total assay activity was
indirectly related to cystatin C concentration, and the relationship was statistically significant (p < 0.001, Spearman r = -0.861). (B) Total cystatin C
activity was directly related to its own concentration, and the correlation was strong and significant (p < 0.001, Spearman r = 0.883).

trends in mean cystatin C concentration and did not
reach statistical significance (Table 3). Cystatin C activity
ratios were calculated for all samples by dividing the
total cystatin C activity by the total cystatin C concentration for each sample. Our results suggest that the average protease inhibitory activity per unit of cystatin C
was equivalent across all groups (Table 3).
Finally, to fully control for differences in mean cystatin
C concentration among diagnostic groups, we paired select data from each group for statistical comparison.
Subsets of samples with matched cystatin C concentrations were selected from each group, generating three
diagnostic subgroups with identical mean cystatin C protein concentrations (Table 4). We then compared activity
ratios using statistics for repeated measures in order to
identify any differences in the kinetics of cystatin C activity among groups. In this analysis, no significant differences were observed among the three diagnostic
groups, and all trends were eliminated by controlling for
cystatin C protein concentration (Table 4).

Discussion
Prior studies have reported that cystatin C concentrations are decreased in the CSF of ALS patients relative
to healthy controls, but it has been unclear if these reductions in protein level result in proportional reductions in cysteine protease inhibitory activity. To address
this important question, we modified a papain inhibition

assay to allow for the direct measurement cystatin C
functional activity in human CSF. The assay performed
with low inter- and intra-assay variability, and allowed
the reliable evaluation of cystatin C activity in multiple
CSF samples from ALS patients and controls. Notably,
this assay measures only the activity of cystatin C at its
primary active site, which interacts with papain-like cysteine proteases. Therefore, the experimental findings of
this study only apply to the activity of cystatin C against
its primary ligands, and do not address its interactions
with legumain-like cysteine proteases.
As expected, cystatin C concentration demonstrated a
strong, direct relationship with the magnitude of its inhibitory activity (Figure 2). This confirms that CSF
cystatin C is biologically active against papain-like cysteine proteases, and that there does not appear to be significant variability in the activity state of the protein
among individual subjects.
Cystatin C concentration also demonstrated a strong,
indirect relationship with the overall activity of the papain assay (Figure 2). This indicates that CSF induces an
overall inhibitory effect on papain-mediated protease activity, and that this effect is highly dependent upon
cystatin C concentration. Additionally, the strength of
the correlations between cystatin C concentration and
both its own activity (Figure 2B) and total papain assay
activity (Figure 2A) were nearly identical in magnitude
(r of 0.883 and -0.861, respectively). This, along with

Table 3 Comparison of cystatin C concentration, papain assay activity, cystatin C activity, and cystatin C activity ratio
among experimental groups
Mean cystatin C concentration ± SD

Mean assay activity ± SD

Mean cystatin C activity ± SD

Mean activity ratio ± SD

ALS (n = 23)

3.09 ± 1.10

1744 ± 919

2663 ± 762

887 ± 131

DC (n = 23)

3.51 ± 1.07

1547 ± 980

2868 ± 850

829 ± 133

HC (n = 23)

3.84 ± 1.13

1302 ± 742

3124 ± 634

843 ± 138

p-value

0.077

0.247

0.124

0.312

For each diagnostic group, the mean cystatin C protein concentration in the CSF (μg/ml), papain inhibitory assay activity in raw CSF, and cystatin C activity in CSF
treated with anti-cystatin C antibody are shown. The right column depicts the mean activity ratio determined by dividing the total cystatin C activity by the total
cystatin C concentration for each sample. No differences among experimental groups reached statistical significance by one-way ANOVA. Assay activity units are
listed in RFU/min.
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Table 4 Repeated measures assessment of cystatin C activity
Mean cystatin
C concentration (μg/ml) ± SD

Mean assay
activity ± SD

Mean cystatin C
activity ± SD

Mean activity
ratio ± SD

ALS (n = 16)

3.54 ± 1.03

1381 ± 798

3006 ± 652

875 ± 132

DC (n = 16)

3.54 ± 1.05

1476 ± 1009

2939 ± 827

842 ± 149

HC (n = 16)

3.53 ± 1.03

1433 ± 782

3010 ± 691

875 ± 121

p-value

0.597

0.796

0.843

0.859

When samples were paired across groups by CSF cystatin C concentration, there were no significant differences in papain assay activity, cystatin C activity, or
cystatin C activity ratio among the three diagnostic groups. Assay activity units are listed as RFU/min.

Table 2 data indicating that cystatin C antibody can
completely block papain inhibition in CSF, suggests that
any other endogenous papain-like cysteine proteases and
alternate cysteine protease inhibitors that are present in
human CSF contribute only minimally to the measured
assay activity. Therefore, cystatin C is likely the dominant cysteine protease inhibitor in human CSF, and plays
a critical role in the regulation of cysteine proteasemediated proteolysis in this setting. While prior studies
have shown that cystatin C protein levels are enriched in
the CSF versus the blood and the protein is often
detected in proteomic studies of the CSF [16,17], our
data suggests it is the primary cysteine protease inhibitor
in the CSF. It should be noted that if cystatin C concentrations approach saturating concentrations for their selected cysteine proteases in the CSF, then small changes
in concentration between individuals or subject groups
may not translate to significant physiological changes in
inhibitory activity.
When the data were divided into diagnostic groups,
comparable correlations were maintained between
cystatin C concentration and both its own activity and
total papain assay activity in each group (Table 3). Activity ratios were then calculated for each patient as the
total cystatin C activity divided by the total cystatin C
concentration, and the resulting mean values were nearly identical between the three experimental groups
(Tables 3 and 4). However the large intragroup variations suggest that cystatin C may not be useful as an individual biomarker for ALS but could be useful in a
panel of disease biomarkers.
Reduced CPI activity within the CSF of ALS or other
neurologic disease patients may contribute to either
toxic or protective pathways related to disease pathogenesis. Cystatin C has been reported to exhibit neurotoxic
effects when injected into the rodent brain [18], and
when directly applied to primary neuronal cultures [19].
However, cystatin C also exhibits neuroprotective effects
both in vivo [20] and in vitro [21], and potential
neuroprotective pathways of cystatin C have been more
thoroughly characterized [22]. The protective function
that appears most relevant to ALS is the regulation of
extracellular cathepsins and calpains, which are released

as part of physiological processes or in response to CNS
damage or stress. The levels of these proteases may be
elevated in ALS and other diseases due to increased expression [23,24], secretion by activated microglia [25],
and release by dying neurons [24,26-29]. Therefore, the
reduced CSF cystatin C activity in ALS may be inadequate to counteract the apparent increase in protease
activity, resulting in protease-mediated CNS damage.
Extracellular cystatin C also may be internalized by
motor neurons and/or glial cells, and subsequently affect
intracellular processes. Efficient cystatin C uptake has
been demonstrated with multiple non-neuronal human
cell lines [30]. If this process also occurs in the human
CNS, reduced extracellular cystatin C concentration
could result in reduced uptake and abnormal deficiencies in intracellular cystatin C activity. Intracellular cathepsins and calpains both appear to be up-regulated in
ALS, and can contribute to the induction of apoptosis
[23,24]. Therefore, deficiencies in intracellular cystatin C
could potentially lead to apoptosis through the loss of a
protective mechanism. Alternatively, reduced extracellular cystatin C levels may reflect increased cellular uptake
in response to increased intracellular levels of cathepsins
and calpains.

Conclusions
We have determined that the functional activity of
cystatin C within the CSF can be effectively measured by
a papain inhibition assay, and that CSF cystatin C activity is directly proportional to its concentration in ALS
patients and controls. Our data indicates that cystatin C
is the predominant cysteine protease inhibitor in the human CSF.
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